Laboratory Co. of America Holdings (NYSE:LH) Holdings Lifted by Mirae Asset Global Investments Co. Ltd.

Mirae Asset Global Investments Co. Ltd. increased its stake in Laboratory Co. of America Holdings (NYSE:LH - Free Report) by 28.5% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 9,394 shares of the medical research company's stock after acquiring an additional 2,081 shares during the period. Mirae Asset Global Investments Co. Ltd.'s holdings in Laboratory Co. of America were worth $2,162,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently bought and sold shares of LH. AMF Tjanstepension AB raised its stake in shares of Laboratory Co. of America by 37.0% in the 3rd quarter. AMF Tjanstepension AB now owns 86,026 shares of the medical research company's stock valued at $19,232,000 after acquiring an additional 23,221 shares during the period. CWM LLC increased its stake in shares of Laboratory Co. of America by 41.0% in the third quarter. CWM LLC now owns 7,107 shares of the medical research company's stock worth $1,588,000 after buying an additional 2,068 shares during the last quarter. UMB Bank n.a. acquired a new stake in Laboratory Co. of America in the third quarter valued at $84,000. Exchange Traded Concepts LLC grew its holdings in Laboratory Co. of America by 1,962.5% during the 3rd quarter. Exchange Traded Concepts LLC now owns 990 shares of the medical research company's stock worth $221,000 after acquiring an additional 942 shares in the last quarter. Finally, Birch Hill Investment Advisors LLC raised its stake in shares of Laboratory Co. of America by 0.9% in the 3rd quarter. Birch Hill Investment Advisors LLC now owns 140,358 shares of the medical research company's stock valued at $31,367,000 after purchasing an additional 1,269 shares in the last quarter. Institutional investors and hedge funds own 95.94% of the company's stock.

Laboratory Co. of America Stock Performance

LH stock traded up $4.16 during trading on Thursday, reaching $245.31. 485,466 shares of the company's stock were exchanged, compared to its average volume of 609,361. Laboratory Co. of America Holdings has a 1-year low of $191.97 and a 1-year high of $258.59. The company's fifty day moving average price is $236.92 and its 200-day moving average price is $230.55. The company has a quick ratio of 1.30, a current ratio of 1.44 and a debt-to-equity ratio of 0.67. The firm has a market cap of $20.52 billion, a PE ratio of 27.81, a P/E/G ratio of 1.84 and a beta of 1.07.

Laboratory Co. of America (NYSE:LH - Get Free Report) last issued its quarterly earnings results on Thursday, February 6th. The medical research company reported $3.45 earnings per share for the quarter, topping analysts' consensus estimates of $3.40 by $0.05. Laboratory Co. of America had a net margin of 5.73% and a return on equity of 15.29%. On average, research analysts expect that Laboratory Co. of America Holdings will post 15.96 EPS for the current fiscal year.

Laboratory Co. of America Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, March 12th. Stockholders of record on Thursday, February 27th will be issued a $0.72 dividend. The ex-dividend date is Thursday, February 27th. This represents a $2.88 annualized dividend and a dividend yield of 1.17%. Laboratory Co. of America's dividend payout ratio (DPR) is 32.65%.

Insider Buying and Selling

In other Laboratory Co. of America news, CEO Adam H. Schechter sold 6,121 shares of the company's stock in a transaction on Tuesday, February 11th. The stock was sold at an average price of $244.62, for a total value of $1,497,319.02. Following the transaction, the chief executive officer now owns 86,445 shares of the company's stock, valued at approximately $21,146,175.90. This represents a 6.61 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Kerrii B. Anderson sold 1,000 shares of the firm's stock in a transaction on Tuesday, January 7th. The stock was sold at an average price of $235.00, for a total value of $235,000.00. Following the sale, the director now directly owns 12,722 shares of the company's stock, valued at approximately $2,989,670. This represents a 7.29 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 24,504 shares of company stock valued at $5,905,692 over the last three months. Company insiders own 0.85% of the company's stock.

Wall Street Analyst Weigh In

LH has been the subject of several research analyst reports. HSBC raised Laboratory Co. of America from a "hold" rating to a "buy" rating in a report on Wednesday, October 30th. Barclays decreased their price objective on shares of Laboratory Co. of America from $271.00 to $260.00 and set an "equal weight" rating for the company in a report on Friday, February 7th. Jefferies Financial Group increased their target price on shares of Laboratory Co. of America from $275.00 to $290.00 and gave the stock a "buy" rating in a report on Thursday, February 6th. Piper Sandler lifted their price target on shares of Laboratory Co. of America from $240.00 to $260.00 and gave the company a "neutral" rating in a report on Monday. Finally, UBS Group dropped their price objective on shares of Laboratory Co. of America from $293.00 to $286.00 and set a "buy" rating on the stock in a research note on Tuesday, January 28th. Three investment analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $265.31.

About Laboratory Co. of America

Labcorp Holdings, Inc engages in providing medical testing services. The company was founded on April 16, 2024 and is headquartered in Burlington, NC.